LEGN LEGEND BIOTECH CORP

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.

Investors and other interested parties may join the live audio webcast of the call via this

A replay of the webcast and earnings news release will be available through the section of Legend Biotech’s website under the section approximately two hours after the call concludes.

ABOUT LEGEND BIOTECH

With over 2,800 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at , and follow us on .

INVESTOR CONTACT:

Jessie Yeung

Tel: (732) 956-8271

PRESS CONTACT:

Alexandra Ventura

Tel: (732) 850-5598





EN
29/10/2025

Underlying

LEGNLEGEND BIOTECH CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEGEND BIOTECH CORP

 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and F...

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show stronger immune fitness and a more immunocompetent TME when CARVYKTI® is used earlier in the treatment journey Eighty percent of as-treated patients in CARTITUDE-4 with standard-risk cytogenetics remained progression-free and off treatment at 30 ...

4h / 48m 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cel...

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia 31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and immunology indications SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, today announced the official opening and ribbon cutting of its new, state-of-the-art ...

November 13, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Reports Third Quarter 2025 Results and Recent Highlight...

Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to include overall survival benefit versus standard of care Over 9,000 patients treated to dateInitiated CARVYKTI® commercial production at Tech Lane facility in BelgiumCash and cash equivalents, and time deposits of approximately $1.0 billion, as of September 30, 2025 SOMERSET, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a gl...

November 12, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech Announces 10 Presentations at the 67th American Society...

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that it will present two oral presentations and seven poster presentations on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) f...

November 3, 2025 1 EN
 PRESS RELEASE
Free
LEGN LEGEND BIOTECH ...

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 ...

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this A replay of the webcas...

October 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch